Exp Mol Med.
2015 May;47(5):e165. 10.1038/emm.2015.24.
An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib
- Affiliations
-
- 1Disease Model Research Laboratory, Aging Intervention Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea. dyyu10@kribb.re.kr
- 2Department of Bioscience and Biotechnology, Bio/Molecular Informatics Center, Konkuk University, Seoul, Korea.
- 3Asan Institute for Life Sciences, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea.
- 4Development and Differentiation Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea.
- 5World Class Institute, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Chungbuk, Korea.
- KMID: 2155657
- DOI: http://doi.org/10.1038/emm.2015.24
Abstract
- Redox adaptation is an important concept that explains the mechanisms by which cancer cells survive under persistent endogenous oxidative stress and become resistant to certain anticancer agents. To investigate this concept, we determined the expression levels of peroxiredoxins (Prxs), antioxidant enzymes in drug-resistant non-small cell lung carcinoma cells. Prx II was remarkably increased only in A549/GR (gefitinib-resistant) cells compared with A549 cells, consistent with methylation/demethylation. Prx II was highly methylated in the A549 cells but was demethylated in the A549/GR cells. The elevated expression of Prx II resulted in the downregulation of reactive oxygen species (ROS) and cell death and upregulation of cell cycle progression in the A549/GR cells. When Prx II mRNA in the A549/GR cells was knocked down, the levels of ROS and apoptosis were significantly recovered to the levels of the controls. In addition, signaling molecules involved in apoptosis were increased in the A549/GR-shPrx II cells. There was no difference in the expression of MAPK/ERK between the A549/GR cells and A549/GR-shPrx II cells, but the phosphorylation of JNK was increased in the A549/GR cells and was markedly decreased in the A549/GR-shPrx II cells. Colony number and tumor growth were significantly decreased in the A549/GR-shPrx II cells compared with the A549/GR cells. Our findings suggest that Prx II has an important role in cancer cell survival via the modulation of signaling molecules involved in apoptosis and the phosphorylation of JNK by the downregulation of ROS levels in A549/GR cells.
MeSH Terms
-
Animals
Antineoplastic Agents/*therapeutic use
Apoptosis/drug effects
Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/metabolism/pathology
Cell Line, Tumor
Drug Resistance, Neoplasm
Female
Humans
Lung/drug effects/metabolism/pathology
Lung Neoplasms/*drug therapy/genetics/metabolism/pathology
Mice, Inbred BALB C
Mice, Nude
Oxidative Stress/drug effects
Peroxiredoxins/*genetics/metabolism
Quinazolines/*therapeutic use
Reactive Oxygen Species/metabolism
Antineoplastic Agents
Peroxiredoxins
Quinazolines
Reactive Oxygen Species
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Enhanced Sensitivity to Gefitinib after Radiation in Non-Small Cell Lung Cancer Cells
- Enhancement of Sensitivity of Human Lung Cancer Cell Line to TRAIL and Gefitinib by IGF-1R Blockade
- Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer
- Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis
- A case of leptomeningeal metastasis from adenocarcinoma of the lung improved by treatment with Gefitinib
